Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

NCT03250676 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03250676
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03250676 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Multicenter, Open Label Trial of H3B-6545, a Covalent Antagonist of Estrogen Receptor Alpha, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
August 23, 2017
Completion date
October 26, 2023
Enrollment
151 (actual)
Sites
39

Conditions

As the registry lists them; a condition with its own page is linked.

breast adenocarcinoma, breast cancer, breast cancer female, breast neoplasms, cancer, breast, er positive, estrogen receptor positive tumor, estrogen-receptor positive breast cancer